Get started
Author

Massimo Massaia

Observed names: M MASSAIA, M Massaia, M Massaia., M. Massaia, M. Massaia., MASSAIA M, MASSAIA, Massimo, MASSIMO MASSAIA, Massaia M, Massaia M., Massaia Massimo, Massaia, Massimo, Massimo M., Massimo MASSAIA
Observed institutions: Lyon 1 Université, National Institutes of Health, University of Minnesota, University of Arizona, Inserm, Institut Pasteur, The Royal Free Hospital, Yale University, Medizinische Hochschule Hannover, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Fondazione Ricerca Molinette, Azienda Ospedaliero Universitaria San Giovanni Battista, Rochester General Hospital, A. O. Ordine Mauriziano di Torino, Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo, Scripps Clinic, University of Arizona Cancer Center, University of Turin, University of Bologna
ORCID: 0000-0002-0021-1428
Observed ORCID: 0000-0002-0021-1428
OpenAlex ID: A5012807744
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
2020 · Francesco Passamonti, Chiara Cattaneo, et al. · The Lancet Haematology · 556
PDF
A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
2007 · Benedetto Bruno, Marcello Rotta, et al. · New England Journal of Medicine · 504
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25− into CD25+ T regulatory cells
2006 · Antonio Curti, Simona Pandolfi, et al. · Blood · 409
PDF
Zoledronic acid repolarizes tumour‐associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway
2009 · Marta Coscia, Elena Quaglino, et al. · Journal of Cellular and Molecular Medicine · 286
PDF
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
2007 · Roberto Piva, Bruce Ruggeri, et al. · Blood · 259
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
2015 · Davide Rossi, Lodovico Terzi-di-Bergamo, et al. · Blood · 217
Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy
2010 · Vincenzo Squadrone, Massimo Massaia, et al. · Intensive Care Medicine · 184
Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease
1990 · R Foa, M Massaia, et al. · Blood · 177
PDF
Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy
1999 · Massimo Massaia, Paolo Borrione, et al. · Blood · 149
Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol‐anchored lymphocyte differentiation antigen ecto‐5′‐nucleotidase (CD73).
1990 · L. F. Thomson, J. M. Ruedi, et al. · Tissue Antigens · 133
Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma
2005 · S Mariani, M Muraro, et al. · Leukemia · 128
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma
2011 · Luisa Giaccone, Barry Storer, et al. · Blood · 122
Chlorambucil plus rituximab with or without maintenance rituximab as first‐line treatment for elderly chronic lymphocytic leukemia patients
2014 · Robin Foà, Ilaria Del Giudice, et al. · American Journal of Hematology · 113
PDF
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase
2006 · A Curti, M Aluigi, et al. · Leukemia · 113
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia
2009 · D Rossi, C Lobetti Bodoni, et al. · Leukemia · 105
PDF
Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid
2007 · Francesca Fiore, Barbara Castella, et al. · Blood · 105
Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
2009 · Antonio Palumbo, Sara Bringhen, et al. · Blood · 98
PDF
Distribution of terminal deoxynucleotidyl transferase and purine degradative and synthetic enzymes in subpopulations of human thymocytes.
1982 · D D F Ma, T A Sylwestrowicz, et al. · The Journal of Immunology · 92
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+
2018 · F. Morandi, D. Marimpietri, et al. · OncoImmunology · 85
PDF
The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells
2017 · Barbara Castella, Joanna Kopecka, et al. · Nature Communications · 84
PDF
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO).
2004 · Giovanni Barosi, Mario Boccadoro, et al. · PubMed · 79
PDF
Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between Vγ9Vδ2 T Cells, αβ CD8+ T Cells, Regulatory T Cells, and Dendritic Cells
2011 · Barbara Castella, Chiara Riganti, et al. · The Journal of Immunology · 77
Antitumor vaccination: where we stand.
2000 · M Bocchia, V Bronte, et al. · PubMed · 76
Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis.
1989 · M Boccadoro, F Marmont, et al. · Journal of Clinical Oncology · 75
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma
2015 · Barbara Castella, Myriam Foglietta, et al. · OncoImmunology · 74
PDF
Works count: 382
Citation count: 7,675
H-index: 48
I10-index: 118
Year
Topic
Type